Xvivo Perfusion AB chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 12.56
Dividend & YieldN/A£ (N/A)
Beta N/A
Market capitalization 43.18M
Operating cash flow 5.5M
ESG Scores unknown

Company description

Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.

Sector: - Industry:

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -10.93M
Total Cashflows From Investing Activities -53.2M -83.84M -266.53M -187.7M
Net Borrowings -3.35M -3.35M -5.67M -10.74M
Total Cash From Financing Activities 19.2M 25.55M 482.77M 234.61M
Change To Operating Activities 9.79M 7.32M -10.93M -1.12M
Issuance Of Stock 19.02M 27.43M 487.04M 244.11M
Net Income 12.69M 4.94M -43.73M 8.15M
Change In Cash -8.26M -27.12M 194.29M 44.46M
Effect Of Exchange Rate 2.11M 1.67M -9.68M 9.61M
Total Cash From Operating Activities 23.63M 29.5M -12.27M -12.06M
Depreciation 6.77M 11.12M 13.25M 11.88M
Change To Account Receivables -17.38M -542k 20.58M -8.29M
Other Cashflows From Financing Activities 182k 1.48M 1.39M 1.24M
Change To Netincome 4.59M 1.41M 5.94M -29.25M
Capital Expenditures -6.66M -10.5M -2.63M -10.19M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 47.93M 62.65M 66.74M 54.04M
Income Before Tax 17.5M 5.29M -57.26M 6.67M
Net Income 12.69M 4.94M -43.73M 8.15M
Selling General Administrative 70.47M 85.53M 107.71M 143.38M
Gross Profit 135.95M 162.81M 129.73M 188.28M
Ebit 13.48M 3.97M -44.19M -8.74M
Operating Income 13.48M 3.97M -44.19M -8.74M
Interest Expense -128k -285k -361k -276k
Income Tax Expense 4.81M 351k -13.53M -1.49M
Total Revenue 187.87M 220.84M 179.86M 258.39M
Cost Of Revenue 51.91M 58.02M 50.13M 70.11M
Total Other Income ExpenseNet 4.02M 1.32M -13.08M 15.41M
Net Income From Continuing Ops 12.69M 4.94M -43.73M 8.15M
Net Income Applicable To Common Shares 12.69M 4.94M -43.73M 8.15M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 46.13M 56.97M 141.85M 257.15M
Total Stockholder Equity 540.48M 577.52M 1.01B 1.29B
Other Current Liabilities 3.76M 3.54M 4.95M 31.92M
Total Assets 586.61M 634.49M 1.15B 1.54B
Common Stock 675k 680k 734k 754k
Other Current Assets
Retained Earnings 39.92M 44.86M 1.12M 9.28M
Treasury Stock 13.02M 16.23M -182k 22.09M
Cash 187.06M 159.95M 354.24M 398.7M
Total Current Liabilities 42.57M 52.6M 72.25M 104.52M
Other Stockholder Equity 13.02M 16.23M -182k 22.09M
Property, Plant, and Equipment 15.62M 23.55M 21.33M 26.3M
Total Current Assets 277.68M 259.88M 463.23M 547.53M
Net Tangible Assets 471.24M 505.53M 777.77M 816.56M
Net Receivables 46.92M 49.11M 43.7M 63.91M
Accounts Payable 16.33M 14.41M 14.47M 21.45M


Insider Transactions

Here are the insider transactions of stock shares related to Xvivo Perfusion AB:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Xvivo Perfusion AB. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Xvivo Perfusion AB

Here is the result of two systematic investment strategies applied to Xvivo Perfusion AB. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Xvivo Perfusion AB

The following chart shows the equity curve of the two systematic investment strategies applied to Xvivo Perfusion AB:

Xvivo Perfusion AB automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 0% on the backtest period.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

0.0 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Xvivo Perfusion AB

This is the result of two momentum investment strategies applied to Xvivo Perfusion AB. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Xvivo Perfusion AB

The following chart shows all the entries opened by the momentum investment system on Xvivo Perfusion AB:

Xvivo Perfusion AB momentum entries
  • The first momentum investment strategy would give -1.47% of return on Xvivo Perfusion AB. That represents -5.0£ of latent gain with 341.0£ of employed capital.
  • The second momentum investment strategy would give 0% of return on Xvivo Perfusion AB. That represents 0.0£ of latent gain with 0.0£ of employed capital.
Performance at glance (1Q Momentum)

Performance

-1.47 %

Latent gain

-5.0 £

Invested capital

341.0 £

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Momentum equity curve on Xvivo Perfusion AB

The following chart shows the equity curve of the two momentum strategies applied to Xvivo Perfusion AB:

Xvivo Perfusion AB momentum equity

Note: the dividends potentially given by Xvivo Perfusion AB are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Xvivo Perfusion AB

The following chart shows the employed capital evolution of the two momentum strategies on Xvivo Perfusion AB since the beginning:

Xvivo Perfusion AB

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250£, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000£.


Buy the dip strategy result on Xvivo Perfusion AB

Buy the dip entry openings on Xvivo Perfusion AB

Xvivo Perfusion AB

The performance achieved by the robo-advisor on Xvivo Perfusion AB is 0%. That represents 0.0$ of latent gain with 0.0£ of employed capital. The following chart shows Xvivo Perfusion AB stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Xvivo Perfusion AB, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Equity curve of the strategy applied to Xvivo Perfusion AB

The following chart shows the result of the investment strategy applied to Xvivo Perfusion AB:

Xvivo Perfusion AB

Note: the dividends potentially given by Xvivo Perfusion AB are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Xvivo Perfusion AB

The following chart shows the employed capital evolution since the beginning of the investment strategy on Xvivo Perfusion AB:

Xvivo Perfusion AB

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Xvivo Perfusion AB

In this section, I will compare the three previous investment strategies applied to Xvivo Perfusion AB.

Equity curve comparison on Xvivo Perfusion AB

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Xvivo Perfusion AB investment strategy comparison

Employed capital comparison on Xvivo Perfusion AB

Xvivo Perfusion AB investment comparison

Performance comparison on Xvivo Perfusion AB

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 0% 0.0£ 0.0£ 0.0%
Momentum 1 quarter -1.47% -5.0£ 341.0£ -36.75%
Momentum 2 quarters 0% 0.0£ 0.0£ -0.0%
Non-directional 0% 0.0£ 0.0£ -0.0%
Annualized return comparison

Automatic investment

0.0 %

Momentum 1Q

-0.0 %

Momentum 2Q

-0.0 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Xvivo Perfusion AB:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between Xvivo Perfusion AB and the other stocks. There may be false positives or some missing correlated stocks. If the price of Xvivo Perfusion AB does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Xvivo Perfusion AB
Country Sweden
City Gothenburg
Address MAessans gata 10
Phone 46 3 17 88 21 50
Website www.xvivoperfusion.com
FullTime employees 113
Industry
Sector
Exchange XLON
Ticker 0RKL.XLON
Market www.londonstockexchange.com

Xvivo Perfusion AB ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown